CCR5 blockade in rheumatoid arthritis: A randomised, double-blind, placebo-controlled clinical trial

Annals of the Rheumatic Diseases

Volumn 69, Issue 11, 2010, Pages 2013-2016

  Van Kuijk, Arno W R ^a   Vergunst, Clarissa E ^a   Gerlag, Danielle M ^a   Bresnihan, Barry ^b   Gomez Reino, Juan J ^c   Rouzier, Regine ^d   Verschueren, Patrick C ^e   Van De Leij, Christiaan ^a   Maas, Mario ^a   Kraan, Maarten C ^f   Tak, Paul P ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^c University Hospital of Santiago de Compostela   (Spain)

^d Centre CAP   (France)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; CHEMOKINE RECEPTOR CCR5; PLACEBO; 4 ((4 BROMOPHENYL) (ETHOXYIMINO)METHYL) 1' ((2,4 DIMETHYL 3 PYRIDINYL)CARBONYL) 4' METHYL 1,4' BIPIPERIDINE N OXIDE; 4-((4-BROMOPHENYL)-(ETHOXYIMINO)METHYL)-1'-((2,4-DIMETHYL-3-PYRIDINYL)CARBONYL)-4'-METHYL-1,4'-BIPIPERIDINE N-OXIDE; AMINE OXIDE; ANTIRHEUMATIC AGENT; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; JOINT BIOPSY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; DRUG ANTAGONISM; HOSPITALIZATION; MIDDLE AGED; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CYCLIC N-OXIDES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PIPERIDINES; PYRIDINES; RECEPTORS, CCR5; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77958490037     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.131235     Document Type: Article

References (32)

1. Tak PP, Smeets TJ, Daha MR, et al. Analysis of the synovial cell infiltrate in early rheumatoid synovial tissue in relation to local disease activity. Arthritis Rheum 1997;40:217-25.
2. Vergunst CE, Tak PP. Chemokines: their role in rheumatoid arthritis. Curr Rheumatol Rep 2005;7:382-8.
3. Koch AE. Chemokines and their receptors in rheumatoid arthritis: future targets? Arthritis Rheum 2005;52:710-21.
4. Patel DD, Zachariah JP, Whichard LP. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol 2001;98:39-45.
5. Brühl H, Wagner K, Kellner H, et al. Surface expression of CC- and CXC-chemokine receptors on leucocyte subsets in inflammatory joint diseases. Clin Exp Immunol 2001;126:551-9.
6. Haringman JJ, Smeets TJ, Reinders-Blankert P, et al. Chemokine and chemokine receptor expression in paired peripheral blood mononuclear cells and synovial tissue of patients with rheumatoid arthritis, osteoarthritis, and reactive arthritis. Ann Rheum Dis 2006;65:294-300.
7. Gómez-Reino JJ, Pablos JL, Carreira PE, et al. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum 1999;42:989-92.
8. Garred P, Madsen HO, Petersen J, et al. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol 1998;25:1462-5.
9. Vierboom MP, Zavodny PJ, Chou CC, et al. Inhibition of the development of collagen-induced arthritis in rhesus monkeys by a small molecular weight antagonist of CCR5. Arthritis Rheum 2005;52:627-36.
10. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
11. Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
12. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38 :727-35.
13. Youssef PP, Kraan M, Breedveld F, et al. Quantitative microscopic analysis of inflammation in rheumatoid arthritis synovial membrane samples selected at arthroscopy compared with samples obtained blindly by needle biopsy. Arthritis Rheum 1998;41:663-9.
14. Kraan MC, Reece RJ, Smeets TJ, et al. Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: implications for pathogenesis and evaluation of treatment. Arthritis Rheum 2002;46:2034-8.
15. Gerlag DM, Tak PP. How to perform and analyse synovial biopsies. Best Pract Res Clin Rheumatol 2009;23:221-32.
16. Jahangier ZN, Jacobs JW, Kraan MC, et al. Pretreatment macrophage infiltration of the synovium predicts the clinical effect of both radiation synovectomy and intra-articular glucocorticoids. Ann Rheum Dis 2006;65:1286-92.
17. Kraan MC, Haringman JJ, Ahern MJ, et al. Quantification of the cell infiltrate in synovial tissue by digital image analysis. Rheumatology (Oxford) 2000;39:43-9.
18. Wijbrandts CA, Vergunst CE, Haringman JJ, et al. Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: implications for use of synovial sublining macrophages as a biomarker. Arthritis Rheum 2007;56:3869-71.
19. Haringman JJ, Gerlag DM, Zwinderman AH, et al. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:834-8.
20. Bresnihan B, Pontifex E, Thurlings RM, et al. Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. J Rheumatol 2009;36:1800-2.
21. Reynes J, Rouzier R, Kanouni T, et al. Safety and antiviral effects of a CCR-5 receptor antagonist in HIV-1-infected subjects. Proceedings of 9th Conference on Retroviruses and Oppotunistic Infections, Seattle, Washington, 2002.
22. Gerlag DM, Haringman JJ, Smeets TJ, et al. Effects of oral prednisolone on biomarkers in synovial tissue and clinical improvement in rheumatoid arthritis. Arthritis Rheum 2004;50:3783-91.
23. Smeets TJ, Kraan MC, van Loon ME, et al. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. Arthritis Rheum 2003;48:2155-62.
24. Wijbrandts CA, Remans PH, Klarenbeek PL, et al. Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients. Arthritis Rheum 2008;58:3330-9.
25. Haringman JJ, Kraan MC, Smeets TJ, et al. Chemokine blockade and chronic inflammatory disease: proof of concept in patients with rheumatoid arthritis. Ann Rheum Dis 2003;62:715-21.
26. Gerlag DM, Hollis S, Layton M, Vencovsky J, Szekanecz Z, Braddock M, Tak PP, on behalf of the ESCAPE study investigators. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. Arthritis Rheum, in press.
27. Jiao Z, Wang W, Jia R, et al. Accumulation of FoxP3-expressing CD4+CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis. Scand J Rheumatol 2007;36:428-33.
28. Vergunst CE, Gerlag DM, von Moltke L, et al. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study. Arthritis Rheum 2009;60:3572-81.
29. Vergunst CE, Gerlag DM, Lopatinskaya L, et al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum 2008;58:1931-9. (Pubitemid 351988084)
30. Wang J, Norcross M. Dimerization of chemokine receptors in living cells: key to receptor function and novel targets for therapy. Drug Discov Today 2008;13:625-32.
31. Isik N, Hereld D, Jin T. Fluorescence resonance energy transfer imaging reveals that chemokine-binding modulates heterodimers of CXCR4 and CCR5 receptors. PLoS ONE 2008;3:e3424.
32. Rodríguez-Frade JM, Muñoz LM, Holgado BL, et al. Chemokine receptor dimerization and chemotaxis. Methods Mol Biol 2009;571:179-98.